MDPI and ACS Style
Marcé, S.; Xicoy, B.; GarcÃa, O.; Cabezón, M.; Estrada, N.; Vélez, P.; Boqué, C.; Sagüés, M.; Angona, A.; Teruel-Montoya, R.;
et al. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. J. Clin. Med. 2021, 10, 3146.
https://doi.org/10.3390/jcm10143146
AMA Style
Marcé S, Xicoy B, GarcÃa O, Cabezón M, Estrada N, Vélez P, Boqué C, Sagüés M, Angona A, Teruel-Montoya R,
et al. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. Journal of Clinical Medicine. 2021; 10(14):3146.
https://doi.org/10.3390/jcm10143146
Chicago/Turabian Style
Marcé, SÃlvia, Blanca Xicoy, Olga GarcÃa, Marta Cabezón, Natalia Estrada, Patricia Vélez, Concepción Boqué, Miguel Sagüés, Anna Angona, Raúl Teruel-Montoya,
and et al. 2021. "Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib" Journal of Clinical Medicine 10, no. 14: 3146.
https://doi.org/10.3390/jcm10143146